Supernus Pharmaceuticals, Inc.
SUPN
$50.30
$0.390.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.63% | 4.54% | 5.55% | 11.82% | 8.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.63% | 4.54% | 5.55% | 11.82% | 8.94% |
| Cost of Revenue | -4.75% | -73.26% | -65.75% | -65.75% | -68.02% |
| Gross Profit | 9.20% | 18.71% | 14.96% | 23.23% | 21.25% |
| SG&A Expenses | 48.30% | 13.89% | 4.56% | 1.73% | -0.32% |
| Depreciation & Amortization | 14.72% | 2.94% | -5.11% | -5.97% | -5.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.92% | 9.93% | 4.00% | 2.89% | 0.98% |
| Operating Income | -178.46% | -47.49% | 28.05% | 950.62% | 361.51% |
| Income Before Tax | -150.10% | -128.61% | 119.55% | 1,628.66% | 3,434.49% |
| Income Tax Expenses | -143.66% | -112.67% | -45.11% | 214.45% | 1,552.10% |
| Earnings from Continuing Operations | -152.19% | -132.02% | 1,131.09% | 499.24% | 5,512.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.19% | -132.02% | 1,131.09% | 499.24% | 5,512.84% |
| EBIT | -178.46% | -47.49% | 28.05% | 950.62% | 361.51% |
| EBITDA | -69.75% | -18.65% | 5.64% | 53.54% | 44.79% |
| EPS Basic | -150.75% | -130.58% | 1,146.57% | 496.09% | 5,171.26% |
| Normalized Basic EPS | -142.42% | -36.12% | 34.41% | 472.96% | 260.25% |
| EPS Diluted | -151.70% | -131.88% | 1,219.17% | 478.63% | 14,025.26% |
| Normalized Diluted EPS | -143.32% | -36.04% | 33.64% | 474.02% | 275.60% |
| Average Basic Shares Outstanding | 2.45% | 1.97% | 1.58% | 1.33% | 1.03% |
| Average Diluted Shares Outstanding | 1.15% | 1.28% | 1.68% | 1.83% | -1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |